The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Aclaris Therapeutics, Inc. | COM | 00461U105 | 6,213 | 251,936 | SH | SOLE | 251,936 | 0 | 0 | ||
| Alder BioPharmaceuticals, Inc. | COM | 014339105 | 2,667 | 232,909 | SH | SOLE | 232,909 | 0 | 0 | ||
| Arbutus Biopharma Corporation | COM | 03879J100 | 760 | 150,592 | SH | SOLE | 150,592 | 0 | 0 | ||
| Ascendis Pharma A/S | SPONSORED ADR | 04351P101 | 21,205 | 529,343 | SH | SOLE | 529,343 | 0 | 0 | ||
| Biohaven Pharmaceutical Holding Company Ltd. | COM | G11196105 | 5,758 | 213,435 | SH | SOLE | 213,435 | 0 | 0 | ||
| CymaBay Therapeutics, Inc. | COM | 23257D103 | 20,741 | 2,254,502 | SH | SOLE | 2,254,502 | 0 | 0 | ||
| Denali Therapeutics Inc. | COM | 24823R105 | 1,481 | 94,666 | SH | SOLE | 94,666 | 0 | 0 | ||
| Immunomedics, Inc. | COM | 452907108 | 17,344 | 1,073,272 | SH | SOLE | 1,073,272 | 0 | 0 | ||
| Insmed Incorporated | COM | 457669307 | 27,436 | 879,910 | SH | SOLE | 879,910 | 0 | 0 | ||
| Myokardia, Inc. | COM | 62857M105 | 13,024 | 309,357 | SH | SOLE | 309,357 | 0 | 0 | ||
| OptiNose, Inc. | COM | 68404V100 | 8,505 | 450,000 | SH | SOLE | 450,000 | 0 | 0 | ||
| Rhythm Pharmaceuticals, Inc. | COM | 76243J105 | 5,086 | 175,000 | SH | SOLE | 175,000 | 0 | 0 | ||
| uniQure N.V. | SHS | N90064101 | 12,444 | 635,234 | SH | SOLE | 635,234 | 0 | 0 | ||